Bulk Actives Post Approval Changes (BACPAC): A European Perspective

  • 1 Citations


This article highlights the problems encountered by dedicated active pharmaceutical ingredients (API) and intermediates manufacturers in obtaining Food and Drug Administration (FDA) clearance for changes in their operations, especially process changes. Several suggestions for introducing workable API postapproval change procedures within the framework of the developing FDA Bulk Actives Post Approval Changes (BACPAC) Guidance are presented.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 189

This is the net price. Taxes to be calculated in checkout.

Author information

Correspondence to Chris Oldenhof PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Oldenhof, C. Bulk Actives Post Approval Changes (BACPAC): A European Perspective. Ther Innov Regul Sci 33, 763–768 (1999) doi:10.1177/009286159903300315

Download citation

Key Words

  • Process change
  • Active pharmaceutical ingredients
  • GMP
  • Manufacturing